CO5611158A2 - Metodos y composiciones para tratar toxicidad gastrointestinal inducida por terapia citoablativa - Google Patents
Metodos y composiciones para tratar toxicidad gastrointestinal inducida por terapia citoablativaInfo
- Publication number
- CO5611158A2 CO5611158A2 CO04094999A CO04094999A CO5611158A2 CO 5611158 A2 CO5611158 A2 CO 5611158A2 CO 04094999 A CO04094999 A CO 04094999A CO 04094999 A CO04094999 A CO 04094999A CO 5611158 A2 CO5611158 A2 CO 5611158A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino acid
- oligopeptide
- arg
- norleucine
- amino acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Método para reducir las toxicidades gastrointestinal inducidas por terapia citoablativa, caracterizado porque comprende administrar a un paciente que se somete a terapia citoablativa, una cantidad farmacéuticamente efectiva de un péptido inmunomodulador, en donde el péptido inmunomodulador comprende un oligopéptido que comprende la secuencia de amino ácidos B-X-X-X-B-X-X-X-J-Tyr en donde B es Lys o Arg; X es un amino ácido alifático o aromático; J es Gly, Lys o Arg, en donde los amino ácidos son los L-isómeros, los D-isómeros y norleucina de origen natural.2.- Método de conformidad con la reivindicación 1, caracterizado porque para el oligopéptido, B es Arg; X es un amino ácido no polar alifático de 5 a 6 átomos de carbono incluyendo norleucina, amino ácido aromático o suD-isómero, habiendo al menos 3 del mismo amino ácido nopolar alifático en el oligopéptido; y J es Gly o Arg.3.- Método de conformidad con la reivindicación 2, caracterizado porque para el oligopéptido al menos 5 amino ácidos definidos por X son valina, leucina o norleucina y cualquier amino ácido restante definido por X es Trp o Tyr.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36021102P | 2002-02-26 | 2002-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5611158A2 true CO5611158A2 (es) | 2006-02-28 |
Family
ID=27766201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04094999A CO5611158A2 (es) | 2002-02-26 | 2004-09-23 | Metodos y composiciones para tratar toxicidad gastrointestinal inducida por terapia citoablativa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040110687A1 (es) |
| EP (1) | EP1485118A2 (es) |
| JP (1) | JP2005524650A (es) |
| KR (1) | KR20040094745A (es) |
| CN (1) | CN1642568A (es) |
| AU (1) | AU2003219971A1 (es) |
| CA (1) | CA2477231A1 (es) |
| CO (1) | CO5611158A2 (es) |
| IL (1) | IL163718A0 (es) |
| MA (1) | MA27187A1 (es) |
| MX (1) | MXPA04008290A (es) |
| NO (1) | NO20044064L (es) |
| RU (1) | RU2004128444A (es) |
| WO (1) | WO2003072061A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7498309B2 (en) | 2003-11-29 | 2009-03-03 | Sangstat Medical Corporation | Pharmaceutical compositions for bioactive peptide agents |
| US20080312201A1 (en) * | 2004-09-10 | 2008-12-18 | Patrick Fogarty | Reduced Toxicity Methotrexate Formulations and Methods for Using the Same |
| CN101804197B (zh) * | 2010-05-21 | 2012-05-23 | 魏华 | 一种用于癌症骨转移的药物组合物及其用途 |
| SG11201601891XA (en) * | 2013-09-13 | 2016-04-28 | Soligenix Inc | Novel peptides and analogs for use in the treatment of oral mucositis |
| US11311598B2 (en) | 2013-09-13 | 2022-04-26 | Soligenix, Inc. | Peptides and analogs for use in the treatment of oral mucositis |
| CN111533802B (zh) * | 2020-05-09 | 2022-05-17 | 清华大学深圳国际研究生院 | S-腺苷同型半胱氨酸人工完全抗原、制备方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385888A (en) * | 1987-03-20 | 1995-01-31 | The Regents Of The University Of California | Class I MHC modulation or surface receptor activity |
| US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
| US6162434A (en) * | 1995-05-03 | 2000-12-19 | Sangstat Medical Corporation | Cytomodulating peptide for inhibiting lymphocyte activity |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
| AU761717B2 (en) * | 1997-04-11 | 2003-06-05 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
| US6696545B1 (en) * | 1997-04-11 | 2004-02-24 | Sangstat Medical Corporation | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
-
2003
- 2003-02-26 RU RU2004128444/14A patent/RU2004128444A/ru not_active Application Discontinuation
- 2003-02-26 CN CNA038071843A patent/CN1642568A/zh active Pending
- 2003-02-26 MX MXPA04008290A patent/MXPA04008290A/es not_active Application Discontinuation
- 2003-02-26 JP JP2003570808A patent/JP2005524650A/ja active Pending
- 2003-02-26 US US10/376,647 patent/US20040110687A1/en not_active Abandoned
- 2003-02-26 EP EP03716258A patent/EP1485118A2/en not_active Withdrawn
- 2003-02-26 KR KR10-2004-7013390A patent/KR20040094745A/ko not_active Application Discontinuation
- 2003-02-26 WO PCT/US2003/006333 patent/WO2003072061A2/en not_active Application Discontinuation
- 2003-02-26 IL IL16371803A patent/IL163718A0/xx unknown
- 2003-02-26 CA CA002477231A patent/CA2477231A1/en not_active Abandoned
- 2003-02-26 AU AU2003219971A patent/AU2003219971A1/en not_active Abandoned
-
2004
- 2004-09-20 MA MA27866A patent/MA27187A1/fr unknown
- 2004-09-23 CO CO04094999A patent/CO5611158A2/es not_active Application Discontinuation
- 2004-09-24 NO NO20044064A patent/NO20044064L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20044064L (no) | 2004-11-18 |
| MXPA04008290A (es) | 2004-11-26 |
| CA2477231A1 (en) | 2003-09-04 |
| US20040110687A1 (en) | 2004-06-10 |
| JP2005524650A (ja) | 2005-08-18 |
| RU2004128444A (ru) | 2005-06-10 |
| KR20040094745A (ko) | 2004-11-10 |
| WO2003072061A3 (en) | 2004-07-08 |
| IL163718A0 (en) | 2005-12-18 |
| EP1485118A2 (en) | 2004-12-15 |
| MA27187A1 (fr) | 2005-01-03 |
| CN1642568A (zh) | 2005-07-20 |
| WO2003072061A2 (en) | 2003-09-04 |
| AU2003219971A1 (en) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900002801A (ko) | 당뇨병 치료용 약학적제제 | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| TW343198B (en) | Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them | |
| CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| AU2006350707A1 (en) | Transdermal delivery systems of peptides and related compounds | |
| RU99106518A (ru) | Glp-1 производные | |
| KR20020040787A (ko) | 디펩티딜 펩티다제 ⅳ의 국소용 신규 효능제 | |
| CA2613464A1 (en) | Treatment of dry eye | |
| BR0309877A (pt) | Peptìdeos estimuladores de tecido conectivo | |
| KR950032636A (ko) | 리포펩티드 유도체, 이의 제조방법 및 이의 용도 | |
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| NZ607892A (en) | Tfpi inhibitors and methods of use | |
| AR018501A1 (es) | Derivados de la dolastatina 15 | |
| FI120454B (fi) | Menetelmä farmaseuttisesti käyttökelpoisten biologisesti aktiivisten peptidien valmistamiseksi | |
| SE0002202D0 (sv) | New peptides | |
| RU2008102928A (ru) | Лечение инфекций, вызванных грибками и/или простейшими одноклеточными организмами | |
| CO5640064A2 (es) | Citomodilacion de peptidos para tratar cistitis intersticial | |
| CY1107990T1 (el) | Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων | |
| AR006523A1 (es) | Compuestos ciclicos, inhibidores de la adhesion | |
| CO5611158A2 (es) | Metodos y composiciones para tratar toxicidad gastrointestinal inducida por terapia citoablativa | |
| US20040059088A1 (en) | Short amphipathic peptides with activity against bacteria and intracellular pathogens | |
| CA2334941A1 (en) | Tnf-derived peptides for use in treating oedema | |
| DE69217763D1 (de) | Hexapeptide | |
| CA2248630A1 (en) | Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |